Sign In
Buy BLRX
$3.10
+0.0100 (+0.324%)
At Close: Jul 13, 2026
Synergy was demonstrated in a combination arm of GLIX1 and the PARP inhibitor olaparib at low doses, with substantially better efficacy compared to the control arm and compared to each drug individua
BioLineRx Ltd. (BLRX) Q1 2026 Earnings Call Transcript
10:47am, Wednesday, 27'th May 2026
BioLineRx Ltd. (BLRX) Q1 2026 Earnings Call Transcript
BioLineRx Reports First Quarter 2026 Financial Results and Provides Corporate Update
07:00am, Wednesday, 27'th May 2026
- Announced first patient dosed in Phase 1/2a clinical trial of GLIX1 for treatment of glioblastoma (GBM) - - Announced new GLIX1 data demonstrating potent anti-tumor effect in GBM across multiple in-
TEL AVIV, Israel and OSLO, Norway, May 22, 2026 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a clinical-stage biopharmaceutical company pursuing life-changing therapies in oncology and
BioLineRx to Report First Quarter 2026 Results on May 27, 2026
07:00am, Wednesday, 20'th May 2026
Management to Hold Conference Call at 8:30 a.m. EDT TEL AVIV, Israel, May 20, 2026 /PRNewswire/ -- BioLineRx Ltd.
New preclinical data further demonstrate GLIX1's robust efficacy in a dose-dependent manner, with strong anti-tumor activity observed even at the lowest doses tested Results highlight GLIX1's potentia
BioLineRx and Hemispherian Announce First Patient Dosed in Phase 1/2a Study of GLIX1 for the Treatment of Glioblastoma (GBM)
07:00am, Tuesday, 28'th Apr 2026
Patient was dosed at NYU Langone Health under the supervision of Dr. Alexandra Miller, Chief of Neuro-Oncology & Co-Director of Brain and Spine Tumor Center, Perlmutter Cancer Center Data from the Ph
Hemispherian Initiates Phase 1/2a Clinical Trial of GLIX1 in Glioblastoma
02:30am, Wednesday, 08'th Apr 2026
OSLO, Norway--(BUSINESS WIRE)--Hemispherian AS, a clinical-stage oncology company developing novel small molecule therapeutics, today announced the initiation of a first-in-human Phase 1/2a clinical t
BioLineRx Announces Initiation of Phase 1/2a Study of GLIX1 for the Treatment of Glioblastoma (GBM)
07:00am, Thursday, 26'th Mar 2026
GLIX1, a TET2 activator , is a first -in- class , oral, small molecule targeting DNA damage response in glioblastoma and other cancers GLIX1 has demonstrated potent anti-tumor activity in multip
BioLineRx Ltd. (BLRX) Q4 2025 Earnings Call Transcript
10:43am, Monday, 23'rd Mar 2026
BioLineRx Ltd. (BLRX) Q4 2025 Earnings Call Transcript
BioLineRx Reports 2025 Financial Results and Provides Corporate Update
07:00am, Monday, 23'rd Mar 2026
- On track to initiate Phase 1/2a clinical trial of GLIX1 for treatment of glioblastoma (GBM) by end of this month - - GLIX1 is positioned to potentially address unmet needs for novel and more effect
BioLineRx (BLRX) Projected to Post Quarterly Earnings on Monday
01:04am, Saturday, 21'st Mar 2026
BioLineRx (NASDAQ: BLRX - Get Free Report) is expected to release its Q4 2025 results before the market opens on Monday, March 23rd. Analysts expect the company to announce earnings of ($0.50) per sha
Top Wall Street Forecasters Revamp BioLineRx Expectations Ahead Of Q4 Earnings
02:45am, Friday, 20'th Mar 2026
BioLineRx Ltd. (NASDAQ: BLRX) to release Q4 earnings on March 23. Previous Q3 losses were 22 cents per share, with sales of $427,000. Analysts rate the stock favorably.
BioLineRx to Report 2025 Annual Results on March 23, 2026
07:00am, Monday, 16'th Mar 2026
Management to Hold Conference Call at 8:30 a.m. EDT TEL AVIV, Israel, March 16, 2026 /PRNewswire/ -- BioLineRx Ltd.
BioLineRx Ltd. (BLRX) Q3 2025 Earnings Call Transcript
10:53am, Monday, 24'th Nov 2025
BioLineRx Ltd. ( BLRX ) Q3 2025 Earnings Call November 24, 2025 8:30 AM EST Company Participants Irina Koffler - Managing Director Philip Serlin - Chief Executive Officer Mali Zeevi - Chief Financial
